Speid & Associates

Executive Summary

Speid & Associates is a specialized consulting firm that accelerates drug development and regulatory approval processes for pharmaceutical and biotechnology companies. Founded in 2005 and based in Toronto, the firm offers expert services across the entire drug development lifecycle, from IND-enabling studies to late-phase clinical trials, regulatory submissions, and post-approval pharmacovigilance. With deep expertise in chemistry, manufacturing, and controls (CMC) and various drug delivery modalities including injectables and solid dosage forms, the firm emphasizes strategic regulatory affairs. As the industry evolves with AI/ML integration and advanced therapies, Speid & Associates is well-positioned to guide clients through complex regulatory pathways, leveraging its experience to speed new drugs to market. The firm's consulting model benefits from increasing regulatory complexity and the need for efficient development strategies, positioning it as a trusted partner for biopharma innovators. While not a high-growth venture, its steady demand and niche expertise provide a resilient business foundation. The conviction score reflects moderate but stable upside, driven by secular trends in drug development outsourcing and regulatory specialization.

Upcoming Catalysts (preview)

• 2026Expansion of AI/ML Services in Drug Development70% success
• Q4 2026Strategic Partnership with Major Pharma50% success
• Q3 2026New FDA Guidance on CMC for Advanced Therapies80% success